Get started
Author

Akash Maniam

Observed names: A Maniam, A. Maniam
ORCID: 0000-0001-6189-0105
Observed ORCID: 0000-0001-6189-0105
OpenAlex ID: A5048127155
Neoadjuvant Chemo-Immunotherapy for Early-Stage Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
2024 · Giuseppe Luigi Banna, Mona Ali Hassan, et al. · JAMA Network Open · 117
PDF
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis
2023 · Carlo Messina, Emilio Francesco Giunta, et al. · European Urology Oncology · 45
PDF
Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape
2024 · Hetvi Ganatra, Joecelyn Kirani Tan, et al. · Breast Cancer · 22
PDF
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
2024 · Aruni Ghose, Patricia Lapitan, et al. · Current Oncology Reports · 18
PDF
Factors associated with breast cancer recurrence and survival at Sangre Grande Hospital, Trinidad
2021 · Kimberly Badal, Rehanna Ali, et al. · Cancer Causes & Control · 11
Large‐bore arterial access in the era of structural cardiovascular disease
2020 · Jelani K. Grant, Akash Maniam, et al. · Journal of Cardiac Surgery · 7
PDF
Antibody-Drug Conjugates in urothelial, prostate, and renal cell cancers: A review of current and emerging therapies
2025 · Anne Perera, Naoko Atsumi, et al. · Critical Reviews in Oncology/Hematology · 6
Translating risk-based breast cancer screening to limited-resource settings
2025 · Kimberly Badal, Akash Maniam, et al. · BMC Global and Public Health · 5
PDF
Perioperative Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
2025 · Sarafina Urenna Otis, Giuseppe Luigi Banna, et al. · Current Oncology Reports · 4
Narrative review on immune-related adverse events (irAEs) of immune checkpoint inhibitors in the adjuvant therapy of urological cancers
2025 · Riya Sabharwal, Artur Vysotskyi, et al. · Chinese Clinical Oncology · 4
The Role of Circulating Tumor DNA in Patients Treated with Adjuvant Immune Checkpoint Inhibitors: Clinical Reality or Distant Horizon?
2025 · Michele Maffezzoli, Ria Nagpal, et al. · Current Oncology Reports · 4
Prognostic factors and treatment choice for stage IV, low-volume metastasis hormone-sensitive prostate cancer: cross-sectional study of real-world data
2024 · Mohamed Ibrahim Elewaily, Marina Campione, et al. · Therapeutic Advances in Urology · 3
Unlocking precision: Bispecific T cell engagers and the next frontier in uro-oncology
2025 · Joecelyn Kirani Tan, Sri Vidya Niharika Gullapalli, et al. · Critical Reviews in Oncology/Hematology · 2
A call to action: improving access to cardiac MRI for diagnosis of immune checkpoint inhibitor related myocarditis in low and middle income countries
2025 · Aruni Ghose, Abhinav Kandala, et al. · Cardio-Oncology · 2
PDF
Magnetic Resonance or Computed Tomography and Bone Scan for Staging Metastatic Hormone–Sensitive Prostate Cancer
2025 · Mona Ali Hassan, Shobana Anpalakhan, et al. · Clinical Medicine Insights Oncology · 2
177Lu-PSMA-617 for metastatic prostate cancer in India
2024 · Aruni Ghose, Soirindhri Banerjee, et al. · The Lancet Regional Health - Southeast Asia · 2
PDF
The association between paraneoplastic neurological syndromes (PNS) and urothelial carcinoma – A review of the literature
2024 · Sarafina Urenna Otis, Giuseppe Luigi Banna, et al. · Critical Reviews in Oncology/Hematology · 2
Intelligence-driven data extraction for the breast cancer multidisciplinary team meeting case preparation: Results from a prospective external validation.
2026 · Disha Khanna, Adan Khan, et al. · Journal of Clinical Oncology · 1
The Current Landscape of Artificial Intelligence in Positron Emission Tomography (PET) Imaging Across the Cancer Continuum
2026 · Wut Yee The Zar, Mi Rim Kim, et al. · Journal of Clinical Medicine · 1
PDF
Results of Five Years of a Cancer Patient Navigation Training Program for Limited-Resource Settings in the Caribbean and Africa
2025 · Kimberly Badal, Nalisha Monroe, et al. · JCO Global Oncology · 1
Investigating the Latest Evidence from Phase III Trials Supporting Treatment Options for De novo Clinically Lymph Node-Positive Hormone-Sensitive Prostate Cancer
2025 · Mohamed Ibrahim Elewaily, Akash Maniam, et al. · Current Oncology Reports · 1
Refugees have cancer too
2024 · Mona Ali Hassan, Akash Maniam · ecancermedicalscience · 1
Differences between whole body magnetic resonance imaging (WB-MRI) and chest/abdomen/pelvis computed tomography (CT)/bone scan (CT/B) in patients staged as having metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective comparative study within a single trust in the UK.
2024 · Mona Hassan, Shobana Anpalakhan, et al. · Journal of Clinical Oncology · 1
Non-conventional histologies of prostate cancer: from morphology to biology-driven precision oncology
2026 · Fabiano Flauto, Giuseppe Neola, et al. · The Oncologist
Tolerability, dose modification, and treatment compliance with adjuvant abemaciclib in high-risk early breast cancer: a UK real-world multicentre study (CONCISE)
2026 · H. Abdallah, Y. Owoseni, et al. · ESMO Real World Data and Digital Oncology
Works count: 44
Citation count: 246
H-index: 6
I10-index: 5
Year
Topic
Type